Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …

Despite current therapeutic options metastatic non–small-cell lung cancer (NSCLC) remains
incurable. Targeted therapies have opened new opportunities for several molecular …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

In the last decade, immune-checkpoint inhibitors (ICIs) have become the backbone of
therapy in advanced, non-oncogene driven, non-small cell lung cancer (NSCLC). More …

Lung cancer is the most common cancer and leading cause of cancer death. While targeted
therapies have redefined treatment options for non-small cell lung carcinoma (NSCLC) with …

Lung cancer mortality has decreased over the past decade and can be partly attributed to
advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have …

The emergence of immune checkpoint inhibitors for the treatment of cancer has led to major
changes to the therapeutic landscape of lung cancer. Improvements in overall survival …

Background Immune checkpoint inhibitors (ICI) either alone or in combination with
chemotherapy have expanded our choice of agents for the palliative treatment of non-small …

Background The neoadjuvant use of immune checkpoint inhibitors (ICIs) in resectable non-
small-cell lung cancer (NSCLC) is currently an area of active ongoing research. The place of …

Lung cancer is the most common malignant tumor with the highest mortality, and about 84%
are non-small cell lung cancer (NSCLC). However, only a small proportion of patients with …